By Tony Fong

SAN FRANCISCO (GenomeWeb News) — As Danaher proceeds with the integration of Beckman Coulter, there is "a lot of work still to do in quality and innovation," but progress has been made, Danaher CEO Larry Culp said at the JP Morgan Healthcare Conference here today.

And while the Beckman Coulter business may not improve substantially over a flattish 2011, momentum can be built this coming year into 2013, Culp said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.